A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Clinical trial NCT06103864 · RECRUITING
Trial details
- NCT number
- NCT06103864
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-23
- Primary completion
- 2027-07-28
- Enrollment
- 625
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.